{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:39:12Z","timestamp":1793324352900,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.pharmthera.2023.108356","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T09:29:48Z","timestamp":1675589388000},"page":"108356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The controversial role of beta-blockers in heart failure with preserved ejection fraction"],"prefix":"10.1016","volume":"243","author":[{"given":"Simon","family":"Wernhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papathanasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Luedike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108356_bb0005","first-page":"378","article-title":"Carvedilol improves renal hemodynamics in patients with chronic heart failure","volume":"98","author":"Abraham","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S3056","article-title":"Arterial stiffness, hypertension, and rational use of nebivolol","volume":"5","author":"Agabiti-Rosei","year":"2009","journal-title":"Vascular Health and Risk Management"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ejhf.2010","article-title":"Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction","volume":"23","author":"Ahmad","year":"2021","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0025","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41591-022-02041-5","article-title":"Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: A pre-specified analysis of EMPEROR-preserved","volume":"28","author":"Anker","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9149(97)00320-2","volume":"80","author":"Aronow","year":"1997","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FJC.0b013e31819fd501","article-title":"An in-depth analysis of vasodilation in the management of hypertension: Focus on adrenergic blockade","volume":"53","author":"Bakris","year":"2009","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0040","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","article-title":"ACC\/AHA versus esc\/esh on hypertension guidelines: JACC guideline comparison","volume":"73","author":"Bakris","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0045","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0050","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/eurheartj\/ehz552","article-title":"Invasive left ventricle pressure-volume analysis: Overview and practical clinical implications","volume":"41","author":"Bastos","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction","volume":"56","author":"Borlaug","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0060","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008935","article-title":"The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction","volume":"15","author":"van de Bovenkamp","year":"2022","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2125.1994.tb04342.x","article-title":"Nitric oxide mediated venodilator effects of nebivolol","volume":"38","author":"Bowman","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0070","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: Is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0075","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0080","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0090","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: Results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0095","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.chest.2016.08.1439","article-title":"Clinical relevance of fluid challenge in patients evaluated for pulmonary hypertension","volume":"151","author":"D\u2019Alto","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1751-7176.2010.00386.x","article-title":"Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: Benefits of vasodilating \u03b2-blockers","volume":"13","author":"Deedwania","year":"2011","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ehf2.12281","article-title":"Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction","volume":"5","author":"Dom\u00ednguez","year":"2018","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0115","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1093\/eurheartj\/ehu315","article-title":"Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction","volume":"35","author":"Dorfs","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0120","doi-asserted-by":"crossref","first-page":"3b","DOI":"10.1016\/j.amjcard.2004.01.003","article-title":"Pharmacology of carvedilol","volume":"93","author":"Dulin","year":"2004","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nature Reviews. Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-199754010-00015","article-title":"Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders","volume":"54","author":"Dunn","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0135","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","article-title":"Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy","volume":"79","author":"Dybro","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0140","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0145","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Eichhorn","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019950","article-title":"Simultaneous measurement of lung diffusing capacity and pulmonary hemodynamics reveals exertional alveolar-capillary dysfunction in heart failure with preserved ejection fraction","volume":"10","author":"Fermoyle","year":"2021","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0033-0620(98)80027-3","article-title":"Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol","volume":"41","author":"Feuerstein","year":"1998","journal-title":"Progress in Cardiovascular Diseases"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0160","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/sj.jhh.1000533","article-title":"Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes","volume":"11","author":"Fogari","year":"1997","journal-title":"Journal of Human Hypertension"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0170","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1185\/03007990903533681","article-title":"Effects of beta-blockers on glucose and lipid metabolism","volume":"26","author":"Fonseca","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/CIRCULATIONAHA.112.111302","article-title":"Hemodynamic responses to rapid saline loading: The impact of age, sex, and heart failure","volume":"127","author":"Fujimoto","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2016.11.239","article-title":"The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies","volume":"228","author":"Fukuta","year":"2017","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0185","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijcard.2007.08.077","article-title":"Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms","volume":"126","author":"Giannoglou","year":"2008","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0190","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/AC.65.5.2056244","article-title":"Beta-blockers: Focus on mechanism of action. Which beta-blocker, when and why?","volume":"65","author":"Gorre","year":"2010","journal-title":"Acta Cardiologica"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0200","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary exercise testing: What is its value?","volume":"70","author":"Guazzi","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0205","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ejhf.2601","volume":"24","author":"Guazzi","year":"2022","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0210","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0215","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0220","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2019.10.048","article-title":"Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort","volume":"75","author":"Ho","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/CIRCULATIONAHA.118.039136","article-title":"Differential clinical profiles, exercise responses, and outcomes associated with existing HFpEF definitions","volume":"140","author":"Ho","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jvc.2020.04.002","article-title":"Left ventricular outflow tract pressure gradient changes after carvedilol-disopyramide cotherapy in a cat with hypertrophic obstructive cardiomyopathy","volume":"29","author":"Hori","year":"2020","journal-title":"Journal of Veterinary Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0240","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0245","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","article-title":"Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of beta-blocking agents?","volume":"11","author":"Jacob","year":"1998","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0250","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: The Framingham study","volume":"113","author":"Kannel","year":"1987","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0255","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00240419","article-title":"Cardiac responses to maximal anisotonic isometric contractions during handgrip and leg extension","volume":"71","author":"Kapitaniak","year":"1995","journal-title":"European Journal of Applied Physiology and Occupational Physiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0260","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: The RATE-AF randomized clinical trial","volume":"324","author":"Kotecha","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0265","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0270","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1527-3466.2004.tb00138.x","article-title":"Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol","volume":"22","author":"Kuroedov","year":"2004","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0275","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjmed.2018.07.008","article-title":"Role of high-dose Beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate","volume":"131","author":"Lam","year":"2018","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0280","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies","volume":"338","author":"Law","year":"2009","journal-title":"Bmj"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0285","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.98.12.1184","article-title":"Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials","volume":"98","author":"Lechat","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0290","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus document on beta-adrenergic receptor blockers","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0295","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2014.15241","article-title":"Association between use of \u03b2-blockers and outcomes in patients with heart failure and preserved ejection fraction","volume":"312","author":"Lund","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0300","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized Beta-blocker treatment for high blood pressure dictated by medical comorbidities: Indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0305","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.cardfail.2021.03.010","article-title":"Iron deficiency is associated with impaired biventricular reserve and reduced exercise capacity in patients with unexplained dyspnea","volume":"27","author":"Martens","year":"2021","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0310","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction","volume":"6","author":"Martin","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0315","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jacc.2021.10.025","article-title":"A new Dawn in HCM: Rise of the RCTs","volume":"78","author":"Masri","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0320","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0325","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2022.03.013","article-title":"Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study","volume":"354","author":"Monda","year":"2022","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0335","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1388-9842(03)00054-0","article-title":"Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol","volume":"5","author":"Nodari","year":"2003","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacc.2018.04.039","article-title":"Myocardial injury and cardiac Reserve in Patients with Heart Failure and Preserved Ejection Fraction","volume":"72","author":"Obokata","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0345","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0350","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0355","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0360","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010114","article-title":"Diastolic ventricular interaction in heart failure with preserved ejection fraction","volume":"8","author":"Parasuraman","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0365","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/VHRM.S285907","article-title":"\u03b2-Blockade for patients with hypertension, ischemic heart disease or heart failure: Where are we now?","volume":"17","author":"Pathak","year":"2021","journal-title":"Vascular Health and Risk Management"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0370","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the heart failure association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0375","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0380","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/00004872-200108000-00011","article-title":"Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients","volume":"19","author":"Poirier","year":"2001","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0385","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jacc.2017.05.029","article-title":"Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction","volume":"70","author":"Reddy","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0390","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0395","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2020.07.009","article-title":"Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation","volume":"76","author":"Reddy","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0400","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028013519591","article-title":"\u03b2-Blockers: A review of their pharmacological and physiological diversity in hypertension","volume":"48","author":"Ripley","year":"2014","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0405","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004121","article-title":"Load-independent systolic and diastolic right ventricular function in heart failure with preserved ejection fraction as assessed by resting and handgrip exercise pressure-volume loops","volume":"11","author":"Rommel","year":"2018","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1071-9164(96)80004-2","article-title":"Medium-term effects of beta-blockade on left ventricular mechanics: A double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction","volume":"2","author":"Rousseau","year":"1996","journal-title":"Journal of Cardiac Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0415","first-page":"B19","article-title":"Carvedilol: Preclinical profile and mechanisms of action in preventing the progression of congestive heart failure","volume":"19 Suppl B","author":"Ruffolo","year":"1998","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0420","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1751-7176.2008.08021.x","article-title":"Comparative efficacy of two different beta-blockers on 24-hour blood pressure control","volume":"10","author":"Sarafidis","year":"2008","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0425","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.amjcard.2019.12.048","article-title":"Metoprolol versus carvedilol in patients with heart failure, chronic obstructive pulmonary disease, diabetes mellitus, and renal failure","volume":"125","author":"Sessa","year":"2020","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0430","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0435","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: A secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0440","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0445","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0450","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circulation. Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0455","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the Spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0460","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3389\/fphys.2017.00558","article-title":"Nebivolol desensitizes myofilaments of a hypertrophic cardiomyopathy mouse model","volume":"8","author":"St\u00fccker","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0465","first-page":"1253","article-title":"Left atrial function dynamics during exercise in heart failure: Pathophysiological implications on the right heart and exercise ventilation inefficiency","volume":"10","author":"Sugimoto","year":"2017","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0470","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ejhf.1699","article-title":"Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction","volume":"22","author":"Tamargo","year":"2020","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0475","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): Aa randomised trial","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0480","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/hrt.2006.092379","article-title":"Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: Data from the carvedilol or metoprolol European trial (COMET)","volume":"93","author":"Torp-Pedersen","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0485","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0490","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data from SENIORS (study of effects of Nebivolol intervention on outcomes and Rehospitalization in Seniors with heart failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0495","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","article-title":"Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality","volume":"43","author":"Verbrugge","year":"2022","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0500","doi-asserted-by":"crossref","first-page":"H338","DOI":"10.1152\/ajpheart.00266.2020","article-title":"Heart failure with preserved ejection fraction diminishes peripheral hemodynamics and accelerates exercise-induced neuromuscular fatigue","volume":"320","author":"Weavil","year":"2021","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0505","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2022.10.009","article-title":"Betablockers reduce oxygen pulse increase and performance in heart failure patients with preserved ejection fraction","volume":"370","author":"Wernhart","year":"2023","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0510","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0515","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0520","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ejhf.2146","article-title":"Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction","volume":"23","author":"Wolsk","year":"2021","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0525","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese diastolic heart failure study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0530","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108356_bb0535","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004969","article-title":"Chronotropic incompetence in chronic heart failure","volume":"11","author":"Zweerink","year":"2018","journal-title":"Circulation. Heart Failure"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:27:38Z","timestamp":1759012058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":107,"alternative-id":["S0163725823000207"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108356","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The controversial role of beta-blockers in heart failure with preserved ejection fraction","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108356"}}